Rapid data sharing method and system for microbial medical examination

Abstract

The invention discloses a rapid data sharing method and system for microbial medical examination, and relates to the technical field of data processing.The system comprises a data acquisition unit, a central processing unit, an optimization management unit and a terminal calling unit, and medical drug sensitivity experiments are conducted through the data acquisition unit to acquire microbial examination data; a data processing model is constructed through the central processing unit for analysis and processing, a microbial medical examination report is obtained, an optimal management scheme of microbial examination is output, and then the scheme is received through the optimal management unit so as to perform optimal management operation, so that the quality of microbial medical examination and the stability of data sharing are ensured, and the data sharing efficiency is improved; microbial examination data and a microbial medical examination report are received and retrieved through the terminal calling unit, patient data are retrieved from terminal devices of an outpatient department and an inpatient department, clinical medication auxiliary guidance is achieved, and the data resource utilization rate and the intelligent application level are improved.

Description

Technical Field

[0001] The present invention relates to the technical field of data processing, and particularly to a method and system for rapid data sharing for microbiological medical tests. Background Art

[0002] The rapid data sharing of microbiological medical tests is an important link to achieve precision medicine, improve diagnostic efficiency, and promote clinical decision-making support. With the progress of medical informatization and Internet technology, many data sharing methods and systems based on technologies such as cloud computing, Internet of Things, and artificial intelligence have emerged one after another, but there are still some technical defects.

[0003] In the existing process of sharing microbiological medical test data, there may be problems of insufficient data sharing efficiency and low level of intelligent application. Due to the lack of comprehensiveness and accuracy in the analysis of microbiological medical tests, and the complexity of the microbiological test process, experimental equipment errors and changes in the experimental environment will have a certain impact on the quality of microbiological medical tests, resulting in the defects of poor and unstable data sharing efficiency, and there is a lack of a deep learning algorithm based on data to intelligently evaluate the results of microbiological tests, making it difficult to provide auxiliary guidance for clinical medication.

[0004] In view of the above technical defects, a solution is proposed herein. Summary of the Invention

[0005] The purpose of the present invention is to solve the problems of insufficient data sharing efficiency and low level of intelligent application existing in the prior art, and the resulting defects of insufficient comprehensiveness and accuracy in the analysis of microbiological medical tests, and poor and unstable data sharing efficiency.

[0006] To achieve the above purpose, the present invention adopts the following technical solutions:

[0007] A method for rapid data sharing for microbiological medical tests, comprising the following steps:

[0008] Step 1, collecting microbiological test data: The microbiological test data includes drug sensitivity parameters and management parameters of the microbiological test. By sampling microbiological specimens and conducting medical drug sensitivity tests, the drug sensitivity parameters of the microbiological test are obtained, and by monitoring the equipment and environment during the medical test process, the management parameters of the microbiological test are obtained.

[0009] Step 2: Construct a data processing model to analyze and process the microbial test data. The data processing model includes a drug sensitivity analysis sub-model and an efficiency analysis sub-model. Through the drug sensitivity analysis sub-model, analyze and process the drug sensitivity parameters of the microbial test to obtain a microbial medical test report. Through the efficiency analysis sub-model, analyze and process the management parameters of the microbial test to obtain the quality of the microbial medical test and evaluate the efficiency of data sharing, thereby establishing the influence relationship of experimental equipment and environmental factors on the test quality, and outputting an optimized management plan for the microbial test.

[0010] Step 3: Optimize the management of the microbial laboratory. Perform optimization management operations by receiving the optimized management plan for the microbial test to improve the data sharing efficiency.

[0011] Step 4: Receive and retrieve the microbial test data and the microbial medical test report. Retrieve patient information through the terminal devices in the outpatient department and the inpatient department to achieve auxiliary guidance for clinical medication.

[0012] Furthermore, the specific process of collecting the microbial test data is as follows:

[0013] The microbial test data includes the drug sensitivity parameters and management parameters of the microbial test.

[0014] A1. Obtain the drug sensitivity parameters of the microbial test by sampling microbial specimens and conducting medical drug sensitivity tests in the microbial laboratory.

[0015] The drug sensitivity parameters of the microbial test include microorganism i, antibiotic j, and the drug sensitivity test result U between microorganism i and antibiotic j. Among them, the drug sensitivity test result U includes sensitive S, resistant R, and intermediate I.

[0016] By preliminarily analyzing the drug sensitivity test result U of microorganism i, obtain the antibiotic count vector <sensitive antibiotic count NS, intermediate antibiotic count NI, resistant antibiotic count NR> of microorganism i.

[0017] A2. Obtain the management parameters of the microbial test by monitoring the equipment and environment during the medical test process.

[0018] The management parameters of the microbial test include equipment sharing information and environmental status information.

[0019] The equipment sharing information includes the response time, lag time, transmission speed of the equipment operation, as well as the byte volume, quality, and usage frequency of the shared data.

[0020] The environmental status information includes the specimen sampling temperature of the microorganism, the temperature and pH value of the drug sensitivity culture, as well as the temperature, humidity, and CO2 concentration of the laboratory.

[0021] Furthermore, the specific process of constructing the drug sensitivity analysis sub-model is as follows:

[0022] The drug sensitivity parameters of microbial testing include microorganism i, antibiotic j, and drug sensitivity test result U between microorganism i and antibiotic j, where drug sensitivity test result U includes sensitive S, resistant R, and intermediate I;

[0023] By preliminarily analyzing the drug sensitivity test results U of microorganism i, the antibiotic count vector of microorganism i <sensitive antibiotic count NS, intermediate antibiotic count NI, resistant antibiotic count NR> is obtained;

[0024] Then analyze the patient's infection status and microbial resistance. The specific process is as follows:

[0025] The patient's body is divided into m1 infection areas, any infection area is marked as Z, the number of microbial species in the infection area Z is marked as Nz, any microorganism is marked as Zi, and the content of microorganism Zi is marked as Mzi. The microbial infection coefficient INFz of the infection area Z is obtained by combining the content Mzi of Nz microorganisms, so as to evaluate the infection degree of the infection area Z; and then the comprehensive infection evaluation index INFT of the patient is obtained by combining the microbial infection coefficients INFz of the m1 infection areas, so as to evaluate the comprehensive infection situation of the patient;

[0026] Obtain the drug resistance evaluation index DRi of microorganism i through the antibiotic count vector <sensitive antibiotic count NS, intermediate antibiotic count NI, resistant antibiotic count NR> of microorganism i to evaluate the drug resistance of microorganism i;

[0027] By analyzing the patient's infection situation and combining the microbial resistance, a microbial medical test report is constructed and output to assist physicians in medication control.

[0028] Furthermore, the specific process of constructing the performance analysis sub-model is as follows:

[0029] The device sharing information includes the page response time Tre, the freeze time Tca and the transmission speed Vts of the device operation, as well as the byte volume Mbt, error rate Era and access frequency Afq of the shared data;

[0030] Obtain the experimental equipment management coefficient LEMS through equipment sharing information to evaluate the quality of experimental equipment;

[0031] Environmental status information includes the microbial specimen sampling temperature Wcy, the temperature Wpy and pH value Phy of drug sensitivity culture, and the laboratory temperature Wsy, humidity Hsy and CO2 concentration Csy;

[0032] Set the parameter preprocessing model to preprocess the environmental status information. The specific process is as follows:

[0033] Input parameter x and the laboratory equipment management coefficient LEMS, and construct a fitting function F(x) between parameter x and the laboratory equipment management coefficient LEMS;

[0034] By substituting the environmental status information into the parameter preprocessing model, successively output the data values of the fitting functions of the specimen sampling temperature Wcy of microorganisms, the temperature Wpy and pH value Phy of drug sensitivity culture, as well as the temperature Wsy, humidity Hsy and CO2 concentration Csy of the laboratory, and mark them as the specimen sampling temperature status value δwcy of microorganisms, the temperature status value δwpy of drug sensitivity culture and the pH value status value δphy, as well as the temperature status value δwsy of the laboratory, the humidity status value δhsy and the CO2 concentration status value δcsy;

[0035] Furthermore, comprehensively obtain the laboratory environment management coefficient LNMS to evaluate the management status of the laboratory environment;

[0036] By combining the laboratory equipment management coefficient LEMS and the laboratory environment management coefficient LNMS, establish the influence relationship of laboratory equipment and environmental factors on the quality of microbiological medical tests, output the microbiological medical test quality index IPQU, and evaluate the quality of microbiological medical tests.

[0037] Further, the specific process of outputting the optimized management plan for microbiological tests is as follows:

[0038] Set the risk threshold of the microbiological medical test quality index IPQU as D0. When the microbiological medical test quality index IPQU is lower than the risk threshold D0, optimize the management of laboratory equipment and environmental factors, so as to generate and output the optimized management plan for microbiological tests;

[0039] Among them, the optimized management plan for microbiological tests includes the design plan for parameter adjustment of laboratory equipment and management optimization of the laboratory environment.

[0040] A data rapid sharing system for microbiological medical tests, including a data acquisition unit, a central processing unit, an optimization management unit and a terminal call unit, and the data acquisition unit, the central processing unit, the optimization management unit and the terminal call unit are communicatively connected; A data rapid sharing method for microbiological medical tests applied by this system;

[0041] The data acquisition unit is used to collect microbiological test data: The microbiological test data includes the drug sensitivity parameters and management parameters of microbiological tests;

[0042] The central processing unit is used to construct a data processing model to analyze and process microbial test data: the data processing model includes a drug sensitivity analysis sub-model and an efficiency analysis sub-model. The drug sensitivity parameters of microbial tests are analyzed and processed through the drug sensitivity analysis sub-model to obtain a microbial medical test report; the management parameters of microbial tests are analyzed and processed through the efficiency analysis sub-model to obtain the quality of microbial medical tests and evaluate the efficiency of data sharing, so as to output an optimized management plan for microbial tests.

[0043] The optimization management unit is used to optimize the management of the microbial laboratory: by receiving the optimized management plan for microbial tests, it performs optimization management operations, and after the optimization management operations, it feeds back instructions to the data acquisition unit to re-perform data acquisition and analysis and processing.

[0044] The terminal call unit is used to receive and retrieve microbial test data and microbial medical test reports: by retrieving patient information through the terminal devices in the outpatient department and inpatient department, clinical medication assistance guidance is realized.

[0045] In summary, due to the adoption of the above technical solutions, the beneficial effects of the present invention are:

[0046] The present invention conducts medical drug sensitivity experiments through the data acquisition unit to collect microbial test data, constructs a data processing model through the central processing unit to analyze and process the microbial test data, obtains a microbial medical test report and outputs an optimized management plan for microbial tests, and then the optimization management unit receives the optimized management plan for microbial tests to perform optimization management operations, ensuring the quality of microbial medical tests and the stability of data sharing, improving the efficiency of data sharing, receiving and retrieving microbial test data and microbial medical test reports through the terminal call unit, retrieving patient information from the terminal devices in the outpatient department and inpatient department, realizing clinical medication assistance guidance, and improving the utilization rate of data resources and the level of intelligent application;

[0047] Among them, the present invention processes the drug sensitivity parameters of microbial tests through the drug sensitivity analysis sub-model, analyzes the patient's infection situation and combines the drug resistance of microorganisms to obtain a microbial medical test report, so as to assist the attending physician in targeted medication for the patient; and processes the management parameters of microbial tests through the efficiency analysis sub-model, obtains the quality of microbial medical tests and evaluates the data sharing efficiency, and then establishes the influence relationship of experimental equipment and environmental factors on the quality of microbial medical tests, so as to output an optimized management plan for microbial tests. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 Shows a connection schematic diagram of the system modules of the present invention;

[0049] Figure 2The figure shows a schematic diagram of the steps of the solution flow of the present invention. Detailed implementation mode

[0050] Next, the technical solutions in the embodiments of the present invention will be clearly and completely described in conjunction with the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts belong to the scope of protection of the present invention.

[0051] Embodiment 1:

[0052] As Figure 1 - Figure 2 shown, a method for rapid data sharing for microbiological medical examinations includes the following steps:

[0053] S1, collecting microbiological test data: The microbiological test data includes the drug sensitivity parameters and management parameters of the microbiological test. By sampling microbiological specimens and conducting medical drug sensitivity tests, the drug sensitivity parameters of the microbiological test are obtained, and by monitoring the equipment and environment during the medical test process, the management parameters of the microbiological test are obtained. The specific process is as follows:

[0054] The microbiological test data includes the drug sensitivity parameters and management parameters of the microbiological test;

[0055] A1, by sampling microbiological specimens and conducting medical drug sensitivity tests in a microbiology laboratory, the drug sensitivity parameters of the microbiological test are obtained; The microbiology laboratory is equipped with equipment such as a bacterial incubator and a microbiological drug sensitivity analyzer for medical drug sensitivity test operations;

[0056] The hospital samples microbiological specimens from patients through several departments in the outpatient department and several nursing units in the inpatient department; Among them, the departments in the outpatient department include the obstetrics and gynecology department, hematology department, urology department, orthopedics department for trauma, infectious disease department, etc.; The nursing units in the inpatient department include the respiratory medicine ward, neurosurgery ward, intensive care unit ward, burn and plastic surgery ward, etc.;

[0057] The microbiological samples include urine, secretions, pus, throat swabs, venous blood, ascites, etc.; Among them, the microorganisms include bacteria, fungi, mycoplasmas, chlamydias, etc. For example, common Enterococcus faecalis, Klebsiella pneumoniae, Escherichia coli, Candida albicans, Enterococcus faecium, etc. in urine; Common Ureaplasma urealyticum, Candida albicans, Listeria monocytogenes, Staphylococcus aureus, etc. in secretions;

[0058] In a medical drug sensitivity test, a patient's microbial specimen is placed on a culture medium, and then drug sensitivity discs of various antibiotics or quantitative antibiotic solutions are placed. After culturing, by observing the growth of pathogenic bacteria, the sensitivity of the pathogenic bacteria in the specimen to various antibiotics is judged. Among them, antibiotics generally include amoxicillin, ampicillin, aztreonam, chloramphenicol, meropenem, moxifloxacin, etc., and drug sensitivity tests are carried out with antibiotic solutions of different concentrations. When the result shows S, it indicates that the pathogenic bacteria are highly sensitive to this type of drug. When the result is I, it means that the pathogenic bacteria are moderately sensitive to this type of drug. When the test result shows R, it means that this type of drug has no effect on the pathogenic bacteria.

[0059] The drug sensitivity parameters of microbial testing include microorganism i, antibiotic j, and the drug sensitivity test result U between microorganism i and antibiotic j. Among them, the drug sensitivity test result U includes sensitive S, resistant R, and intermediate I.

[0060] By preliminarily analyzing the drug sensitivity test result U of microorganism i, the antibiotic count vector <sensitive antibiotic count NS, intermediate antibiotic count NI, resistant antibiotic count NR> of microorganism i is obtained.

[0061] A2, by monitoring the equipment and environment during the medical testing process, the management parameters of microbial testing are obtained.

[0062] The management parameters of microbial testing include equipment sharing information and environmental status information.

[0063] The equipment sharing information includes the response time, lag time, and transmission speed of the equipment operation, as well as the byte volume, quality, and usage frequency of the shared data.

[0064] The environmental status information includes the specimen sampling temperature of microorganisms, the temperature and pH value of drug sensitivity culture, as well as the temperature, humidity, and CO2 concentration of the laboratory.

[0065] Among them, when incubating at a temperature below 35°C, the growth rate of most bacteria slows down, and the diffusion rate of antibacterial drugs is also slower. The pH value of the culture medium should be within an acceptable range, such as between 7.2 and 7.4, otherwise it will cause changes in the size of the inhibition zone. An increase in CO2 in the environment will cause a decrease in pH value, thereby affecting the activity of some antibacterial drugs.

[0066] S2. Construct a data processing model to analyze and process the microbial test data: The data processing model includes a drug sensitivity analysis sub-model and an efficiency analysis sub-model. Through the drug sensitivity analysis sub-model, analyze and process the drug sensitivity parameters of the microbial test to obtain a microbial medical test report; through the efficiency analysis sub-model, analyze and process the management parameters of the microbial test to obtain the quality of the microbial medical test and evaluate the efficiency of data sharing, thereby establishing the influence relationship of experimental equipment and environmental factors on the test quality, and output an optimized management plan for the microbial test;

[0067] S2-1. The specific process of constructing the drug sensitivity analysis sub-model is as follows:

[0068] Analyze and process the drug sensitivity parameters of the microbial test through the drug sensitivity analysis sub-model;

[0069] The drug sensitivity parameters of the microbial test include microorganism i, antibiotic j, and the drug sensitivity test result U between microorganism i and antibiotic j. Among them, the drug sensitivity test result U includes sensitive S, resistant R, and intermediate I;

[0070] Any antibiotic j includes the name and concentration of the antibiotic, which is unique; microorganism i includes the name and preset quantity of the microorganism. Perform drug sensitivity tests on the preset quantity of microorganism i and n0 antibiotics j;

[0071] By preliminarily analyzing the drug sensitivity test result U of microorganism i, obtain the antibiotic count vector <sensitive antibiotic count NS, intermediate antibiotic count NI, resistant antibiotic count NR> of microorganism i;

[0072] Analyze the patient's infection situation and the drug resistance of the microorganism:

[0073] S2-101. Divide the patient's body into m1 infection areas. Mark any infection area as Z, mark the number of microorganism species in the infection area Z as Nz, mark any microorganism as Zi, and mark the content of microorganism Zi as Mzi. Combine the contents Mzi of Nz kinds of microorganisms to obtain the microbial infection coefficient INFz of the infection area Z, so as to evaluate the infection degree of the infection area Z; furthermore, combine the microbial infection coefficients INFz of m1 infection areas to obtain the comprehensive infection assessment index INFT of the patient, and evaluate the comprehensive infection situation of the patient; among them, the infection areas are such as the intestinal area, respiratory area, skin area, etc.;

[0074] Comprehensive infection assessment index INFT:

[0075] Among them, λzi refers to the weight coefficient of the content Mzi of microorganism Zi, and λzi is greater than 0. The weight coefficient λzi is preset after being calculated through a large amount of experimental data; when the content Mzi of Nz kinds of microorganisms is higher, the microorganism infection coefficient INFz of the infection area Z is higher, so the more serious the infection degree of the infection area Z is evaluated, and further the more serious the comprehensive infection condition of the patient is evaluated;

[0076] S2-102. Obtain the drug resistance evaluation index DRi of microorganism i through the antibiotic count vector <sensitive antibiotic count NS, intermediate antibiotic count NI, resistant antibiotic count NR> of microorganism i:

[0077]

[0078] Among them, ω1 and ω2 are respectively the weight coefficients of the resistant antibiotic count NR and the sensitive antibiotic count NS, and both ω1 and ω2 are greater than 0. When the resistant antibiotic count NR is higher and the sensitive antibiotic count NS is lower, the drug resistance evaluation index DRi is higher, and the drug resistance of microorganism i is evaluated to be higher;

[0079] Drug resistance means that the antibiotics frequently used in the patient's medical history for a long time will produce drug resistance, changing from sensitive antibiotics to intermediate antibiotics and then to resistant antibiotics, thus generating drug resistance and making the antibiotic ineffective against the microorganism. When there are more types of antibiotics with higher drug resistance, more caution needs to be exercised in using the remaining sensitive antibiotics, including dosage and types;

[0080] S2-103. Construct and output a microbial medical test report by analyzing the patient's infection situation and combining with the drug resistance of microorganisms, so as to assist doctors in drug control;

[0081] The microbial medical test report includes the microorganism infection coefficient INFz of m1 infection areas Z of the patient's body, the comprehensive infection evaluation index INFT of the patient, and the drug resistance evaluation index DRi of Nz kinds of microorganisms i in the infection area Z;

[0082] By analyzing several microorganism species in the patient's specimen, a microbial infection association model is constructed. This model includes the specimen onset locations of multiple microorganisms, the microorganism content and microorganism infection coefficient at each onset location. Among them, the specimen onset locations include the respiratory tract and the intestine, etc. Different infection locations may lead to different clinical symptoms. For example, respiratory tract infection may be accompanied by symptoms such as coughing and expectoration, while intestinal infection may be accompanied by symptoms such as diarrhea and abdominal pain. Thus, through the microbial medical test report, doctors are assisted in targeted and precise drug control;

[0083] S2-2. The specific process of constructing the efficiency analysis sub-model is as follows:

[0084] The management parameters of microbial inspection are analyzed and processed by the performance analysis sub-model;

[0085] S2-201, the equipment sharing information includes the page response time Tre of equipment operation, the carding time Tca, the transmission speed Vts, as well as the byte volume Mbt of shared data, the error rate Era and the access frequency Afq;

[0086] The equipment sharing information is collected by the existing equipment monitoring tool and stored in the equipment work log, and the system obtains the equipment sharing information by accessing the equipment work log;

[0087] The experimental equipment management coefficient LEMS is obtained through the equipment sharing information:

[0088]

[0089] Among them, μ1 and μ2 are the weight coefficients of equipment operation and shared data respectively, and both μ1 and μ2 are greater than 0; when the page response time Tre and the carding time Tca are lower and the transmission speed Vts is higher, it indicates that the equipment operation state is better; when the byte volume Mbt and the error rate Era are lower and the access frequency Afq is higher, it indicates that the data sharing efficiency is higher and the quality is better; furthermore, by combining the equipment operation state and the data sharing quality, the quality of the experimental equipment is comprehensively evaluated. When the experimental equipment management coefficient LEMS is higher, the quality of the experimental equipment is evaluated to be better;

[0090] S2-202, the environmental state information includes the specimen sampling temperature Wcy of microorganisms, the temperature Wpy and pH value Phy of drug sensitivity culture, as well as the temperature Wsy, humidity Hsy and CO2 concentration Csy of the laboratory;

[0091] Set the parameter preprocessing model to preprocess the environmental state information, and the specific process is as follows:

[0092] Input the parameter x and the experimental equipment management coefficient LEMS, and construct a fitting function F(x) between the parameter x and the experimental equipment management coefficient LEMS: F(x) = LEMS = ln[(x - x1)*(x2 - x) + X0];

[0093] Among them, the preset interval [x1, x2] is the standard interval of the parameter x. When the parameter x is within the standard interval, it indicates that the parameter x is in a normal state; when the parameter x is higher or lower than the standard interval, it indicates that the parameter x is in an abnormal state. The higher the amplitude of the parameter x being higher or lower than the standard interval, the higher the degree of abnormality of the parameter x; X0 is an adjustment constant, and the adjustment constant X0 is a preset constant value to ensure that [(x - x1)*(x - x2)+X0] is always greater than 0; when the parameter x is within the standard interval, the higher the data value of the fitting function F(x), the higher the experimental equipment management coefficient LEMS corresponding to the parameter x, indicating that the set value of the parameter x is better.

[0094] By substituting the environmental status information into the parameter preprocessing model, the data values of the fitting functions of the specimen sampling temperature Wcy of microorganisms, the temperature Wpy and pH value Phy of drug sensitivity culture, as well as the temperature Wsy, humidity Hsy and CO2 concentration Csy of the laboratory are output in sequence, and are respectively marked as the specimen sampling temperature status value δwcy of microorganisms, the temperature status value δwpy of drug sensitivity culture and the pH value status value δphy, as well as the temperature status value δwsy of the laboratory, the humidity status value δhsy and the CO2 concentration status value δcsy.

[0095] Furthermore, the experimental environment management coefficient LNMS is comprehensively obtained:

[0096] LNMS = (δwcy) ε1 +(δwpy * δphy) ε2 +(δwsy * δhsy * δcsy) ε3 ;

[0097] Among them, ε1, ε2 and ε3 are the weight coefficients of the microbial specimen, drug sensitivity culture and laboratory environment respectively, and ε1, ε2 and ε3 are all greater than 1; when the specimen sampling temperature status value δwcy of microorganisms, the temperature status value δwpy of drug sensitivity culture and the pH value status value δphy, as well as the temperature status value δwsy of the laboratory, the humidity status value δhsy and the CO2 concentration status value δcsy are higher, the higher the experimental environment management coefficient LNMS, indicating that the management setting status of the experimental environment is better.

[0098] S2 - 203, by combining the experimental equipment management coefficient LEMS and the experimental environment management coefficient LNMS, the influence relationship of the experimental equipment and environmental factors on the quality of microbial medical testing is established, and the microbial medical testing quality index IPQU is output: IPQU = α1 LEMS +α2 LNMS ;

[0099] Among them, α1 and α2 are the weight coefficients of the experimental equipment management coefficient LEMS and the experimental environment management coefficient LNMS respectively, and both α1 and α2 are greater than 0; when the experimental equipment management coefficient LEMS and the experimental environment management coefficient LNMS are higher, the microbial medical test quality index IPQU is higher, indicating that the microbial medical test quality is better;

[0100] The specific process of outputting the optimized management plan for microbial tests is as follows:

[0101] Set the risk threshold of the microbial medical test quality index IPQU as D0. When the microbial medical test quality index IPQU is lower than the risk threshold D0, optimize the management of experimental equipment and environmental factors, so as to generate and output the optimized management plan for microbial tests;

[0102] Among them, the optimized management plan for microbial tests includes the design plan for parameter adjustment of experimental equipment and management optimization of the experimental environment;

[0103] S3. Optimize the management of the microbial laboratory: Receive the optimized management plan for microbial tests and perform optimized management operations to ensure the quality of microbial medical tests and the stability of data sharing, so as to improve the data sharing efficiency;

[0104] By setting the comparison factors of the experimental equipment management coefficient LEMS and the experimental environment management coefficient LNMS as R1 and R2 respectively, and making comparisons, design and obtain the optimized management plan for microbial tests;

[0105] When the experimental equipment management coefficient LEMS is lower than the comparison factor R1, adjust the parameters of the experimental equipment, such as upgrading the server configuration, increasing bandwidth, CPU and other technical management means;

[0106] When the experimental environment management coefficient LNMS is lower than the comparison factor R2, optimize the management of the experimental environment, such as controlling the air conditioning facilities, adjusting the temperature and humidity of the experimental environment, and reducing the CO2 concentration, etc.;

[0107] S4. Receive and retrieve microbial test data and microbial medical test reports: Retrieve patient information through the terminal devices of the outpatient department and the inpatient department, so as to realize clinical medication assistance and guidance;

[0108] The microbial medical test report includes the microbial infection coefficient INFz of m1 infection areas Z of the patient's body, the comprehensive infection assessment index INFT of the patient, and the drug resistance assessment index DRi of Nz kinds of microorganisms i in the infection area Z;

[0109] The specific process of adjuvant medication needs to be combined with the actual infection situation of the patient: by analyzing several microbial species in the patient's specimens, a microbial infection association model is constructed. This model includes the disease occurrence locations of specimens of multiple microorganisms, the microbial content at each disease occurrence location, and the microbial infection coefficient. Among them, the disease occurrence locations of specimens include the respiratory tract, intestines, etc. Different infection locations may lead to different clinical symptoms. For example, respiratory tract infections may be accompanied by symptoms such as coughing and expectoration, while intestinal infections may be accompanied by symptoms such as diarrhea and abdominal pain. Through data such as the microbial content and microbial infection coefficient at the disease occurrence location, it assists the attending physician in administering targeted medications to the patient. Finally, through the microbial medical test report, it assists the physician in precise medication control.

[0110] A data rapid sharing system for microbial medical testing includes a data acquisition unit, a central processing unit, an optimization management unit, and a terminal calling unit. The data acquisition unit, the central processing unit, the optimization management unit, and the terminal calling unit are communicatively connected; this system applies the above-mentioned data rapid sharing method for microbial medical testing.

[0111] The data acquisition unit is used to collect microbial test data: The microbial test data includes the drug sensitivity parameters and management parameters of microbial tests. By sampling microbial specimens and conducting medical drug sensitivity tests, the drug sensitivity parameters of microbial tests are obtained, and by monitoring the equipment and environment during the medical test process, the management parameters of microbial tests are obtained.

[0112] The central processing unit is used to construct a data processing model to analyze and process the microbial test data: The data processing model includes a drug sensitivity analysis sub-model and an efficiency analysis sub-model. By analyzing and processing the drug sensitivity parameters of microbial tests through the drug sensitivity analysis sub-model, a microbial medical test report is obtained; by analyzing and processing the management parameters of microbial tests through the efficiency analysis sub-model, the quality of microbial medical tests is obtained and the efficiency of data sharing is evaluated, thereby establishing the influence relationship of experimental equipment and environmental factors on the test quality, and outputting an optimized management plan for microbial tests.

[0113] The optimization management unit is used to optimize the management of the microbial laboratory: By receiving the optimized management plan for microbial tests, it performs optimization management operations, and after the optimization management operations, it feeds back instructions to the data acquisition unit to re-monitor and analyze the data to improve the data sharing efficiency.

[0114] The terminal calling unit is used to receive and retrieve microbial test data and microbial medical test reports: By retrieving patient information through the terminal devices in the outpatient department and inpatient department, clinical medication assistance guidance is realized.

[0115] In summary, the present invention conducts medical drug sensitivity experiments through a data acquisition unit to collect microbial test data, constructs a data processing model through a central processing unit to analyze and process the microbial test data, obtains a microbial medical test report and outputs an optimized management plan for microbial tests, and then receives the optimized management plan for microbial tests through an optimization management unit to perform optimization management operations, ensuring the quality of microbial medical tests and the stability of data sharing, improving the data sharing efficiency, receiving and retrieving microbial test data and microbial medical test reports through a terminal call unit, retrieving patient information from the terminal devices of the outpatient department and the inpatient department, realizing clinical medication assistance and guidance, and improving the utilization rate of data resources and the level of intelligent application;

[0116] The data processing model of the present invention processes the drug sensitivity parameters of microbial tests through a drug sensitivity analysis sub-model, analyzes the patient's infection situation and combines it with the drug resistance of microorganisms to obtain a microbial medical test report, thereby assisting the attending physician in prescribing targeted medications for the patient; and processes the management parameters of microbial tests through an efficiency analysis sub-model, obtains the quality of microbial medical tests and evaluates the data sharing efficiency, and establishes the influence relationship of experimental equipment and environmental factors on the quality of microbial medical tests, thereby outputting an optimized management plan for microbial tests.

[0117] The setting of the size of the interval and threshold is for the convenience of comparison. Regarding the size of the threshold, it depends on the amount of sample data and the base quantity set by those skilled in the art for each group of sample data; as long as it does not affect the proportional relationship between the parameters and the quantified values.

[0118] The above formulas are all dimensionless and take their numerical calculations. The formulas are obtained by collecting a large amount of data and performing software simulations to obtain a formula closest to the actual situation. The preset parameters in the formulas are set by those skilled in the art according to the actual situation;

[0119] The above is only a preferred specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art within the technical scope disclosed by the present invention, according to the technical solution and inventive concept of the present invention, making equivalent substitutions or changes, should be covered by the protection scope of the present invention.

Claims

1. A method for rapid data sharing for microbiological medical testing, characterized in that: The following steps are involved: Step 1: Collecting microbiological test data: Microbiological test data includes drug sensitivity parameters and management parameters of microbiological tests. The drug sensitivity parameters of microbiological tests are obtained by sampling microbiological specimens and conducting medical drug sensitivity tests, and the management parameters of microbiological tests are obtained by monitoring the equipment and environment during the medical test process; Step 2: construct a data processing model to analyze and process the microbial test data: the data processing model includes a drug sensitivity analysis sub-model and an efficacy analysis sub-model. The drug sensitivity analysis sub-model is used to analyze and process the drug sensitivity parameters of the microbial test to obtain a microbial medical test report; Through the performance analysis sub-model, the management parameters of microbiological testing are analyzed and processed to obtain the quality of microbiological medical testing and evaluate the efficiency of data sharing, so as to establish the influence relationship between experimental equipment and environmental factors on the quality of testing, and output the optimization management plan of microbiological testing; Step 3: Optimize the management of microbiological laboratories: Optimize management operations by receiving the optimized management plan for microbiological testing to improve data sharing efficiency; Step 4: Receive and retrieve microbiological test data and microbiological medical test reports: retrieve patient information through the terminal equipment in the outpatient department and inpatient department to provide auxiliary guidance for clinical medication.

2. A method for rapid data sharing for microbiological medical testing according to claim 1, characterized in that: The specific process of collecting microbiological test data is as follows: Microbiological testing data include drug sensitivity parameters and management parameters of microbiological testing; A1, by sampling microbial specimens and conducting medical drug sensitivity tests in microbiological laboratories, the drug sensitivity parameters of microbiological tests can be obtained; The drug sensitivity parameters of microbial testing include microorganism i, antibiotic j, and drug sensitivity test result U between microorganism i and antibiotic j, where drug sensitivity test result U includes sensitive S, resistant R, and intermediate I; By preliminarily analyzing the drug sensitivity test results U of microorganism i, the antibiotic count vector of microorganism i <sensitive antibiotic count NS, intermediate antibiotic count NI, resistant antibiotic count NR> is obtained; A2, by monitoring the equipment and environment during medical testing, to obtain the management parameters of microbiological testing; Management parameters for microbiological testing include equipment sharing information and environmental status information; Device sharing information includes the response time, freeze time and transmission speed of the device operation, as well as the byte volume, quality and usage frequency of the shared data; Environmental status information includes the sample sampling temperature of microorganisms, the temperature and pH value of drug sensitivity culture, and the temperature, humidity and CO2 concentration of the laboratory.

3. A method for rapid data sharing for microbiological medical testing according to claim 2, characterized in that: The specific process of constructing the drug sensitivity analysis sub-model is as follows: The drug sensitivity parameters of microbial testing include microorganism i, antibiotic j, and drug sensitivity test result U between microorganism i and antibiotic j, where drug sensitivity test result U includes sensitive S, resistant R, and intermediate I; By preliminarily analyzing the drug sensitivity test results U of microorganism i, the antibiotic count vector of microorganism i <sensitive antibiotic count NS, intermediate antibiotic count NI, resistant antibiotic count NR> is obtained; Then analyze the patient's infection status and microbial resistance. The specific process is as follows: The patient's body is divided into m1 infection areas, any infection area is marked as Z, the number of microbial species in the infection area Z is marked as Nz, any microorganism is marked as Zi, and the content of microorganism Zi is marked as Mzi. The microbial infection coefficient INFz of the infection area Z is obtained by combining the content Mzi of Nz microorganisms, so as to evaluate the infection degree of the infection area Z; and then the comprehensive infection evaluation index INFT of the patient is obtained by combining the microbial infection coefficients INFz of the m1 infection areas, so as to evaluate the comprehensive infection situation of the patient; Obtain the drug resistance evaluation index DRi of microorganism i through the antibiotic count vector <sensitive antibiotic count NS, intermediate antibiotic count NI, resistant antibiotic count NR> of microorganism i to evaluate the drug resistance of microorganism i; By analyzing the patient's infection situation and combining the microbial resistance, a microbial medical test report is constructed and output to assist physicians in medication control.

4. A method for rapid data sharing for microbiological medical testing according to claim 3, characterized in that: The specific process of constructing the performance analysis sub-model is as follows: The device sharing information includes the page response time Tre, the freeze time Tca and the transmission speed Vts of the device operation, as well as the byte volume Mbt, error rate Era and access frequency Afq of the shared data; Obtain the experimental equipment management coefficient LEMS through equipment sharing information to evaluate the quality of experimental equipment; Environmental status information includes the microbial specimen sampling temperature Wcy, the temperature Wpy and pH value Phy of drug sensitivity culture, and the laboratory temperature Wsy, humidity Hsy and CO2 concentration Csy; Set the parameter preprocessing model to preprocess the environmental status information. The specific process is as follows: Input parameter x and experimental equipment management coefficient LEMS, and construct a fitting function F(x) between parameter x and experimental equipment management coefficient LEMS; By substituting the environmental status information into the parameter preprocessing model, the data values ​​of the fitting functions of the microbial specimen sampling temperature Wcy, the temperature Wpy and pH value Phy of the drug sensitivity culture, and the temperature Wsy, humidity Hsy and CO2 concentration Csy of the laboratory are output in sequence, and are marked as the microbial specimen sampling temperature state value δwcy, the temperature state value δwpy and pH value state value δphy of the drug sensitivity culture, and the temperature state value δwsy, humidity state value δhsy and CO2 concentration state value δcsy of the laboratory respectively; then the experimental environment management coefficient LNMS is comprehensively obtained to evaluate the management status of the experimental environment; By combining the experimental equipment management coefficient LEMS and the experimental environment management coefficient LNMS, the relationship between the influence of experimental equipment and environmental factors on the quality of microbiological medical testing is established, and the microbiological medical testing quality index IPQU is output to evaluate the quality of microbiological medical testing.

5. A method for rapid data sharing for microbiological medical testing according to claim 4, characterized in that: The specific process of the optimized management plan for output microbiological testing is as follows: The risk threshold of the microbiological medical laboratory quality index IPQU is set to D0. When the microbiological medical laboratory quality index IPQU is lower than the risk threshold D0, the laboratory equipment and environmental factors are optimized and managed, thereby generating and outputting an optimized management plan for microbiological testing. Among them, the optimization management plan for microbial testing includes parameter adjustment plan for experimental equipment and management optimization plan for the experimental environment.

6. A data rapid sharing system for microbiological medical testing, characterized by: The system comprises a data acquisition unit, a central processing unit, an optimization management unit and a terminal calling unit, and the data acquisition unit, the central processing unit, the optimization management unit and the terminal calling unit are communicatively connected with each other; the system applies a method for rapid data sharing for microbiological medical testing as described in any one of claims 1 to 5 above; The data collection unit is used to collect microbiological test data: the microbiological test data includes drug sensitivity parameters and management parameters of microbiological tests; The central processing unit is used to construct a data processing model to analyze and process the microbial test data: the data processing model includes a drug sensitivity analysis sub-model and an efficacy analysis sub-model. The drug sensitivity analysis sub-model is used to analyze and process the drug sensitivity parameters of the microbial test, thereby obtaining a microbial medical test report; Through the performance analysis sub-model, the management parameters of microbiological testing are analyzed and processed to obtain the quality of microbiological medical testing and evaluate the efficiency of data sharing, thereby outputting the optimized management plan for microbiological testing; The optimization management unit is used to optimize the management of the microbiological laboratory: it performs optimization management operations by receiving the optimization management plan for microbiological testing, and after the optimization management operation, it feeds back instructions to the data acquisition unit to re-collect data and analyze and process; The terminal calling unit is used to receive and retrieve microbiological test data and microbiological medical test reports: patient information is retrieved through the terminal equipment of the outpatient department and inpatient department, thereby realizing auxiliary guidance of clinical medication.

Images